000130352 001__ 130352
000130352 005__ 20240228143427.0
000130352 0247_ $$2doi$$a10.1093/carcin/bgw007
000130352 0247_ $$2pmid$$apmid:26785731
000130352 0247_ $$2ISSN$$a0143-3334
000130352 0247_ $$2ISSN$$a1460-2180
000130352 0247_ $$2altmetric$$aaltmetric:5024643
000130352 037__ $$aDKFZ-2017-05431
000130352 041__ $$aeng
000130352 082__ $$a610
000130352 1001_ $$0P:(DE-HGF)0$$aPrakash, Hridayesh$$b0$$eFirst author
000130352 245__ $$aLow doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: lesson from insulinoma.
000130352 260__ $$aOxford$$bOxford Univ. Press$$c2016
000130352 3367_ $$2DRIVER$$aarticle
000130352 3367_ $$2DataCite$$aOutput Types/Journal article
000130352 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524812532_4217
000130352 3367_ $$2BibTeX$$aARTICLE
000130352 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130352 3367_ $$00$$2EndNote$$aJournal Article
000130352 520__ $$aTumor infiltrating iNOS+ macrophages under the influence of immunosuppressive tumor microenvironment gets polarized to tumor-promoting and immunosuppressive macrophages, known as tumor-associated macrophages (TAM). Their recruitment and increased density in the plethora of tumors has been associated with poor prognosis in cancer patients. Therefore, retuning of TAM to M1 phenotype would be a key for effective immunotherapy. Radiotherapy has been a potential non-invasive strategy to improve cancer immunotherapy and tumor immune rejection. Irradiation of late-stage tumor-bearing Rip1-Tag5 mice twice with 2 Gy dose resulted in profound changes in the inflammatory tumor micromilieu, characterized by induction of M1-associated effecter cytokines as well as reduction in protumorigenic and M2-associated effecter cytokines. Similarly, in vitro irradiation of macrophages with 2 Gy dose-induced expression of iNOS, NO, NFκBpp65, pSTAT3 and proinflammatory cytokines secretion while downregulating p38MAPK which are involved in iNOS translation and acquisition of an M1-like phenotype. Enhancement of various M2 effecter cytokines and angiogenic reprogramming in iNOs+ macrophage depleted tumors and their subsequent reduction by 2 Gy dose in Rip1-Tag5 transgenic mice furthermore demonstrated a critical role of peritumoral macrophages in the course of gamma irradiation mediated M1 retuning of insulinoma.
000130352 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130352 588__ $$aDataset connected to CrossRef, PubMed,
000130352 650_7 $$2NLM Chemicals$$aCytokines
000130352 7001_ $$0P:(DE-HGF)0$$aKlug, Felix$$b1
000130352 7001_ $$aNadella, Vinod$$b2
000130352 7001_ $$aMazumdar, Varadendra$$b3
000130352 7001_ $$aSchmitz-Winnenthal, Hubertus$$b4
000130352 7001_ $$aUmansky, Liudmila$$b5
000130352 773__ $$0PERI:(DE-600)1474206-8$$a10.1093/carcin/bgw007$$gVol. 37, no. 3, p. 301 - 313$$n3$$p301 - 313$$tCarcinogenesis$$v37$$x1460-2180$$y2016
000130352 909CO $$ooai:inrepo02.dkfz.de:130352$$pVDB
000130352 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130352 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130352 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130352 9141_ $$y2016
000130352 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000130352 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130352 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130352 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130352 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130352 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCARCINOGENESIS : 2015
000130352 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130352 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130352 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130352 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130352 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130352 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130352 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130352 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130352 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130352 9201_ $$0I:(DE-He78)G808-20160331$$kG808$$lIMT IM Platform$$x0
000130352 980__ $$ajournal
000130352 980__ $$aVDB
000130352 980__ $$aI:(DE-He78)G808-20160331
000130352 980__ $$aUNRESTRICTED